Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-06-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2023年第二次临时股东大会决议
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 2023 second extraordinary shareholders' meeting of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions. The key content is the election of a new director due to a resignation. There are no financial statements or detailed financial data presented. The document focuses on board and senior management changes, specifically the appointment of a new director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1852 characters), and it is not a report publication announcement or a certification. Hence, the classification is MANG with high confidence.
2023-06-27 Chinese
北京德恒（杭州）律师事务所关于江西新赣江药业股份有限公司2023年第二次临时股东大会的法律意见
Regulatory Filings
2023-06-27 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the authorization, amounts, types of financial products purchased, risk control measures, and related board and shareholder meeting resolutions. The document is a regulatory disclosure about the company's cash management activities involving idle raised funds, including amounts and counterparties. It does not contain financial statements, audit opinions, or detailed financial results. It is not a full financial report but a specific update on capital/financing activities related to the use of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2862 characters, which is consistent with an announcement rather than a full report. Confidence is high given the clear focus on cash management of raised funds and related disclosures.
2023-06-19 Chinese
关于募集资金余额转出并注销募集资金专项账户的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the transfer and cancellation of a special fundraising account, detailing the use and balance of funds raised in a 2021 directed share issuance. It includes specifics about the fundraising amount, usage, account closure, and related board resolutions. The document is relatively short (1836 characters) and serves as a formal notification of the status and closure of fundraising accounts rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or analysis typical of Annual Reports (10-K), Interim Reports (IR), or Capital/Financing Updates (CAP). Instead, it is a regulatory announcement about fundraising account management and closure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-13 Chinese
关于召开2023年第二次临时股东大会通知公告（提供网络投票)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 second extraordinary general meeting of shareholders (临时股东大会) for Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendees, agenda items including the election of a new director, and registration procedures. It does not contain financial statements or results, nor is it a transcript or presentation. It is an announcement about the meeting itself, not the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-06-06 Chinese
第二届董事会第二十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including appointments of senior management and board members, and decisions related to company operations such as the use of raised funds and scheduling a shareholders meeting. It includes details about meeting attendance, voting results, and compliance with legal and procedural requirements. There is no financial data or report content, but rather a disclosure of board decisions and management changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-06-06 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.